Clinical trials: Pseudomonas Infection
Bronchiectasis Adult, Pseudomonas Aeruginosa Infection
Tobramycin Inhalation Solution for Pseudomonas Aeruginosa Eradication in Bronchiectasis
People with bronchiectasis are prone to Pseudomonas aeruginosa (PA) infections, which can become chronic and lead to increased death rates and disease severity.
- Trial name
- ERASE (NCT06093191)
- Testing
- Tobramycin Inhalant Product, Ciprofloxacin 750 MG, Natural saline inhalation
- Where
- 60 sites in China
- Volunteers
- 371 people
- Sponsor
- Jin-Fu Xu
Infections, Infection, Bacterial
Development and Validation of (Bio)Sensors for the Identification of Pathogens
The recent COVID-19 pandemic has revealed the need to develop tests that are accurate, rapid, and inexpensive for the diagnosis of infectious diseases.
- Conditions
- Infections, Infection, Bacterial, Infection Viral, Infection, Parasite
- Trial name
- NCT06548841
- Testing
- Nanobiotechnology platforms
- Where
- Italy
- Volunteers
- 149 people
- Sponsor
- University of Bologna
Pseudomonas Infections, Pseudomonas Septicemia
Monocyte Profiles in Critically Ill Patients With Pseudomonas Aeruginosa Sepsis
The present study focuses on patients with Pseudomonas aeruginosa (PSA) sepsis. The aim of the present study is to find out whether the M1 (pro-inflammatory) or M2 (anti-inflammatory) phenotype predominates in blood monocytes in…
- Conditions
- Pseudomonas Infections, Pseudomonas Septicemia, Pseudomonas; Pneumonia, Pseudomonal Bacteraemia
- Trial name
- MIPSA (NCT03044223)
- Where
- Germany
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- University of Ulm
Pseudomonas Aeruginosa, Colonization, Asymptomatic
Carbapenem-resistant Pseudomonas Aeruginosa: the SAMPAN Study.
Pseudomonas aeruginosa causes severe infections in hospitalized patients. The worldwide emergence of carbapenem-resistant P. aeruginosa (CRPA) makes infections by these pathogens almost untreatable.
- Conditions
- Pseudomonas Aeruginosa, Colonization, Asymptomatic, Nosocomial Infection
- Trial name
- SAMPAN (NCT05282082)
- Where
- 3 sites in Indonesia, Italy and 1 more
- Volunteers
- 2,105 people, healthy volunteers welcome
- Sponsor
- Erasmus Medical Center
Ceftolozane/Tazobactam, Imipenem/Relebactam
In Vitro Activity of Ceftolozane/Tazobactam and Imipenem/Relebactam in Clinical Isolates of Pseudomonas Aeruginosa and Enterobacterales Collected From Hematology and Oncology Patients
The purpose of the ACTHEON Study is to evaluate the in vitro activity of ceftolozane-tazobactam, imipenem-relebactam and comparator agents (amoxicillin- clavulanate, piperacillin-tazobactam, ceftazidime, cefotaxime, cefepime…
- Conditions
- Ceftolozane/Tazobactam, Imipenem/Relebactam, Hematology and Oncology
- Trial name
- ACTHEON (NCT04196608)
- Testing
- Ceftolozane/tazobactam, imipenem- relebactam
- Where
- Spain
- Volunteers
- 1,005 people
- Sponsor
- Emilio Bouza
Non-cystic Fibrosis Bronchiectasis, Pseudomonas Aeruginosa
Study to Evaluate the Safety, Phage Kinetics, and Efficacy of Inhaled AP-PA02 in Subjects With Non-Cystic Fibrosis Bronchiectasis and Chronic Pulmonary Pseudomonas Aeruginosa Infection
A phase 2, multi-center, double-blind, randomized, placebo-controlled study to evaluate the safety, phage kinetics, and efficacy of inhaled AP-PA02 administered in subjects with non-cystic fibrosis bronchiectasis and chronic…
- Conditions
- Non-cystic Fibrosis Bronchiectasis, Pseudomonas Aeruginosa, Lung Infection
- Trial name
- Tailwind (NCT05616221)
- Testing
- AP-PA02
- Where
- 23 sites in United States
- Volunteers
- 48 people
- Sponsor
- Armata Pharmaceuticals, Inc.
CARRIER STATE
Efficacy of a Probiotic or Fecal Microbiota Transplantation (FMT) on the Eradication of Rectal Multidrug-resistant Gram-negative Bacilli (MDR-GNB) Carriage (PROFTMDECOL)
The working hypothesis is that in patients who are rectal carriers of MDR-GNB (Multi drug-resistant gram negative bacilli), the rate and speed of eradication of the carrier status obtained with NAA regimens are insufficient and…
- Trial name
- PROFTMDECOL (NCT04431934)
- Testing
- PROBIOTIC, FMT REGIMEN
- Where
- Spain
- Volunteers
- 437 people
- Sponsor
- Hospital Clinic of Barcelona
Carbapenem-Resistant Enterobacteriaceae Infection, Bloodstream Infection
Seven Versus 14 Days of Antibiotic Therapy for Multidrug-resistant Gram-negative Bacilli Infections
Antimicrobial resistance is a major global problem, particularly in hospital-acquired infections (HAIs). Gram-negative bacilli (GNB), including Enterobacterales, Pseudomonas aeruginosa, and Acinetobacter baumannii, are among the…
- Conditions
- Carbapenem-Resistant Enterobacteriaceae Infection, Bloodstream Infection, Severe Infection, Pseudomonas Aeruginosa
- Trial name
- OPTIMISE (NCT05210387)
- Testing
- Duration of therapy
- Where
- 29 sites in Brazil
- Volunteers
- 107 people
- Sponsor
- Hospital Moinhos de Vento
Healthy
Study Assessing Safety and Immunogenicity of IC43 Vaccination Against Pseudomonas Aeruginosa in Healthy Volunteers
The objective is to confirm the optimal dose of IC43 in regard to immunogenicity, safety and tolerability.
- Trial name
- NCT00778388
- Testing
- IC43
- Where
- 3 sites in Austria, Germany
- Volunteers
- 157 people, healthy volunteers welcome
- Sponsor
- Valneva Austria GmbH
Cystic Fibrosis, Infection
Anti-Inflammatory Pulmonal Therapy of CF-Patients With Amitriptyline and Placebo
Our data indicate that the CFTR-molecule functions as a transporter for sphingosine-1-phosphate and sphingosine or regulates the uptake of these sphingolipids by epithelial cells.
- Conditions
- Cystic Fibrosis, Infection, Pseudomonas Aeruginosa
- Trial name
- NCT00515229
- Testing
- amitriptyline
- Where
- Germany
- Volunteers
- 18 people
- Sponsor
- University Hospital Tuebingen
Cystic Fibrosis in Adults, Chronic Colonization With Pseudomonas Aeruginosa
Detection of Reductions in Cystic Fibrosis Airway Inflammation While Using Aztreonam Lysine Solution
In cystic fibrosis, there is a critical need for better predictors of treatment response. The investigators have identified a panel of white blood cell biomarkers which can be directly measured as a blood test in subjects with…
- Trial name
- NCT01736839
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- National Jewish Health
Cystic Fibrosis
International Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Cystic Fibrosis Patients With P. Aeruginosa
The purpose of this study was to evaluate the safety and efficacy of a 28-day course of aztreonam for inhalation solution (AZLI) in patients with cystic fibrosis (CF) and lung infection due to Pseudomonas aeruginosa (PA).
- Trial name
- AIR-CF1 (NCT00112359)
- Testing
- AZLI 75 mg three times a day (TID)
- Where
- 53 sites in United States, Australia and 2 more
- Volunteers
- 166 people
- Sponsor
- Gilead Sciences
Bronchiectasis With Pseudomonas Aeruginosa Colonization
A Study to Evaluate the Efficacy, Safety, and PK of AZD0292 Administered IV in Participants 12 Years of Age and Older With Bronchiectasis and Chronic Pseudomonas Aeruginosa Colonization
AZD0292 is a bispecific IgG1k mAb being evaluated for the prevention of exacerbations in bronchiectasis patients chronically colonized with PsA.
- Trial name
- CLEAR (NCT07088926)
- Testing
- AZD0292
- Where
- 186 sites in United States, Argentina and 23 more
- Volunteers
- 435 people
- Sponsor
- AstraZeneca
Bronchiectasis Adult
Long-term Impact of Inhaled Tobramycin for Pseudomonas Aeruginosa Eradication in Bronchiectasis (ERASE II)
The ERASE II study is a prospective follow-up study designed to assess the long-term impact of successful eradication of Pseudomonas aeruginosa (PA) in patients with bronchiectasis.
- Trial name
- NCT06760273
- Testing
- No Intervention: Observational Cohort
- Where
- 58 sites in China
- Volunteers
- 364 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
Persistent Infection, Cystic Fibrosis
A Study To Evaluate The Safety Of CMTX-101 In People With Cystic Fibrosis
CMTX-101 is a bacterial biofilm disrupting monoclonal antibody being developed as an adjunctive therapy to standard of care antibiotics.
- Trial name
- NCT06159725
- Testing
- CMTX-101
- Where
- 23 sites in United States
- Volunteers
- 43 people
- Sponsor
- Clarametyx Biosciences, Inc.
Pressure Ulcer
Phage Therapy for the Prevention and Treatment of Pressure Ulcers.
This study will evaluate a topical bacteriophage therapy product (BACTELIDE) as an adjunct to standard therapy for the prevention and treatment of pressure ulcers colonized with S. aureus, P. aeruginosa, or K. pneumoniae species.
- Trial name
- NCT04815798
- Testing
- Bacteriophage-loaded Microcapsule Spray, Standard of Care
- Volunteers
- 69 people
- Sponsor
- Precisio Biotix Therapeutics, Inc.
Bronchiectasis
Research on the Mechanism Affecting Progression of Bronchiectasis
Bronchiectasis is a chronic inflammatory respiratory disease defined as the irreversible dilatation of one or more bronchi and is associated with chronic and frequently purulent expectoration, multiple exacerbations and…
- Trial name
- NCT05731427
- Testing
- Pseudomonas aeruginosa colonization infection, Macrolides
- Where
- 3 sites in China
- Volunteers
- 150 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Bronchiectasis
Macrolide Mediates Pulmonary Infection of Pseudomonas Aeruginosa
It is acknowledged that IL-18, as a product of the inflammasome, is involved in host defence against viral and bacterial stimuli by modulating the immune response.
- Trial name
- NCT02491723
- Testing
- Azithromycin
- Where
- China
- Volunteers
- 71 people, healthy volunteers welcome
- Sponsor
- Jin-Fu Xu
Cystic Fibrosis
SAD and MAD of Inhaled AR-501 in Health Adults and P. Aeruginosa Infected Cystic Fibrosis Subjects
This is a Phase 1/2a randomized, double-blind, two-part, dose-ascending, multicenter study of AR-501 (gallium citrate) solution, administered via inhalation, in healthy adult and P.
- Trial name
- NCT03669614
- Testing
- Inhaled AR-501
- Where
- 25 sites in United States
- Volunteers
- 102 people, healthy volunteers welcome
- Sponsor
- Aridis Pharmaceuticals, Inc.
Antibiotic Resistant Strain
Multicenter Evaluation of the Susceptibility of Enterobacteriaceae and Pseudomonas Aeruginosa to Ceftolozane/Tazobactam Combination
Ceftolozane/tazobactam is a new antibiotic with broad spectrum activity. This molecule is currently one of the most active beta lactams against Pseudomonas aeruginosa and its spectrum of activity also includes enterobacteriaceae…
- Trial name
- GMC-9 (NCT03963297)
- Where
- France
- Volunteers
- 747 people
- Sponsor
- Fondation Hôpital Saint-Joseph